| Primary |
| Infection |
16.3% |
| Urinary Tract Infection |
12.4% |
| Pneumonia |
12.1% |
| Hypertension |
8.5% |
| Osteomyelitis |
6.7% |
| Prophylaxis |
6.4% |
| Pain |
5.4% |
| Cellulitis |
4.4% |
| Sepsis |
3.4% |
| Cholecystitis Acute |
3.0% |
| Product Used For Unknown Indication |
3.0% |
| Diverticulitis |
2.9% |
| Diabetic Foot Infection |
2.4% |
| Bacteraemia |
2.1% |
| Escherichia Infection |
2.0% |
| Osteitis |
1.9% |
| Pyelonephritis |
1.8% |
| Skin Ulcer |
1.8% |
| Anaemia |
1.6% |
| Kidney Infection |
1.6% |
|
| Convulsion |
30.0% |
| Hallucination |
5.4% |
| Vomiting |
5.4% |
| Clostridial Infection |
4.5% |
| Death |
4.5% |
| Drug Ineffective |
4.2% |
| Status Epilepticus |
4.2% |
| Grand Mal Convulsion |
4.0% |
| Urticaria |
4.0% |
| Epilepsy |
3.7% |
| No Therapeutic Response |
3.7% |
| Mental Status Changes |
3.2% |
| Pyrexia |
3.2% |
| Rash |
3.2% |
| Sepsis |
3.2% |
| Confusional State |
3.0% |
| Overdose |
2.7% |
| Renal Failure Acute |
2.7% |
| White Blood Cell Count Increased |
2.7% |
| Muscular Weakness |
2.5% |
|
| Secondary |
| Product Used For Unknown Indication |
21.4% |
| Infection |
10.4% |
| Osteomyelitis |
8.4% |
| Urinary Tract Infection |
7.1% |
| Sepsis |
5.2% |
| Skin Ulcer |
5.2% |
| Pneumonia |
4.9% |
| Depression |
3.9% |
| Immunosuppression |
3.9% |
| Hypertension |
3.6% |
| Pyelonephritis |
3.6% |
| Bacterial Infection |
2.6% |
| Drug Use For Unknown Indication |
2.6% |
| Kidney Infection |
2.6% |
| Osteitis |
2.6% |
| Pain |
2.6% |
| Pneumonia Klebsiella |
2.6% |
| Prophylaxis |
2.6% |
| Anaemia |
2.3% |
| Antibiotic Therapy |
2.3% |
|
| Status Epilepticus |
8.9% |
| Vomiting |
7.9% |
| No Therapeutic Response |
6.9% |
| Hallucination, Visual |
5.9% |
| Nausea |
5.9% |
| Septic Shock |
5.9% |
| Encephalopathy |
5.0% |
| Escherichia Test Positive |
5.0% |
| Hepatitis C Positive |
5.0% |
| Neutropenia |
5.0% |
| Convulsion |
4.0% |
| Dysarthria |
4.0% |
| Hallucination |
4.0% |
| Injection Site Rash |
4.0% |
| Partial Seizures |
4.0% |
| Posterior Reversible Encephalopathy Syndrome |
4.0% |
| Renal Failure Acute |
4.0% |
| Wernicke's Encephalopathy |
4.0% |
| White Blood Cell Count Increased |
4.0% |
| Drug Interaction |
3.0% |
|
| Concomitant |
| Drug Use For Unknown Indication |
32.6% |
| Product Used For Unknown Indication |
25.0% |
| Rheumatoid Arthritis |
10.1% |
| Pneumonia |
4.3% |
| Osteoporosis |
4.0% |
| Systemic Lupus Erythematosus |
3.2% |
| Sepsis |
3.0% |
| Tonsil Cancer |
2.6% |
| Infection |
1.9% |
| Multiple Myeloma |
1.9% |
| Urinary Tract Infection |
1.7% |
| Prophylaxis |
1.5% |
| Pain |
1.3% |
| Trismus |
1.2% |
| Nuclear Magnetic Resonance Imaging |
1.1% |
| Nausea |
1.0% |
| Atrial Fibrillation |
0.9% |
| Premedication |
0.9% |
| Crohn's Disease |
0.9% |
| Abdominal Pain |
0.8% |
|
| Wound Infection Staphylococcal |
27.4% |
| Death |
12.1% |
| Progressive Multifocal Leukoencephalopathy |
11.3% |
| Respiratory Failure |
5.6% |
| Sepsis |
5.6% |
| Thrombocytopenia |
4.8% |
| Weight Decreased |
4.0% |
| Thrombophlebitis Superficial |
3.2% |
| Hypotension |
2.4% |
| Leukopenia |
2.4% |
| Pyrexia |
2.4% |
| Stress Fracture |
2.4% |
| Thrombotic Microangiopathy |
2.4% |
| Tremor |
2.4% |
| White Blood Cell Count Increased |
2.4% |
| Wound Complication |
2.4% |
| Asthenia |
1.6% |
| Cellulitis |
1.6% |
| Chills |
1.6% |
| Confusional State |
1.6% |
|
| Interacting |
| Epilepsy |
25.0% |
| Hyperthermia |
25.0% |
| Pneumonia Bacterial |
25.0% |
| Status Epilepticus |
25.0% |
|
| Clonic Convulsion |
50.0% |
| Drug Level Decreased |
50.0% |
|
